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Abstract
Background: Many studies have shown that high-dose proton-pumps inhibitors (PPI) do not further reduce the
rate of rebleeding compared to non-high-dose PPIs but we do not know whether intravenous non-high-dose PPIs
reduce rebleeding rates among patients at low risk (Rockall score < 6) or among those at high risk, both compared
to high-dose PPIs. This retrospective case-controlled study aimed to identify the subgroups of these patients that
might benefit from treatment with non-high-dose PPIs.
Methods: Subjects who received high dose and non-high-dose pantoprazole for confirmed acute PU bleeding at a
tertiary referral hospital were enrolled (n = 413). They were divided into sustained hemostasis (n = 324) and
rebleeding groups (n = 89). The greedy method was applied to allow treatment-control random matching (1:1).
Patients were randomly selected from the non-high-dose and high-dose PPI groups who had a high risk peptic
ulcer bleeding (n = 104 in each group), and these were then subdivided to two subgroups (Rockall score ≥ 6 vs.<
6, n = 77 vs. 27).
Results: An initial low hemoglobin level, serum creatinine level, and Rockall score were independent factors
associated with rebleeding. After case-control matching, the significant variables between the non-high-dose and
high-dose PPI groups for a Rockall score ≥ 6 were the rebleeding rate, and the amount of blood transfused. Case-
controlled matching for the subgroup with a Rockall score < 6 showed that the rebleeding rate was similar for
both groups (11.1% in each group).
Conclusion: Intravenous non-high-dose pantoprazole is equally effective as high-dose pantoprazole when treating
low risk patients with a Rockall sore were < 6 who have bleeding ulcers and high-risk stigmata after endoscopic
hemostasis.
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Acute, non-variceal upper gastrointestinal bleeding is a
common cause of hospitalization and mortality has
remained at 6% to 8% despite recent advances in both
pharmacological and endoscopic therapy [1,2]. The risk
of recurrent bleeding is increased in patients with high-
risk stigmata found by endoscopy. Endoscopic hemosta-
sis is able to control bleeding and reduce the rebleeding
rate, morbidity and even mortality of this disease [3,4].
The success of hemostasis, however, is highly dependent
o nt h ei n t r a g a s t r i cp Ha n ds t u d i e sh a v es h o w nt h a t ,
when the intra-gastric pH is low, platelet function is
impaired and pepsin is activated, which disaggregates
platelet plugs [5,6]. The maintenance of an intragastric
pH above 6.0 allows stabilization of the clot, which
stops peptic ulcer (PU) bleeding and prevents rebleeding
[7,8]. Interestingly, in Hung’s study [9], the time during
which a intragastric pH above 6 was maintained was
similar for both a non-high dose PPI group and a high
dose group (49%, 59%, p = 0.182). This poses the ques-
tion as to what is the optimal dose of PPI that is able to
achieve the required therapeutic goal, This continues to
be a controversial issue in clinical practice. Both the
Vienna and Asia-Pacific consensus recommend intrave-
nous high-dose PPI therapy after successful endoscopic
hemostasis; however, the evidence related to the use of
low-dose PPIs is limited [10,11]. Many studies have
shown that high-dose PPIs do not further reduce the
rate of rebleeding compared to non-high-dose PPIs
[12-14]. Nevertheless, we do not know whether the
effect of intravenous non-high-dose PPIs is able to
reduce the rebleeding rate among patients at low risk
(Rockall score ≤ 6) or among those at high risk, both
compared to high-dose PPIs. We can assume that intra-
venous high-dose PPI therapy is no doubt beneficial
after successful endoscopic hemostasis but non-high
dose treatment may be equally effective among certain
subgroup of patients. If this is true, a change in strategy
with respect to the use of PPIs may be both beneficial
and cost-effective. The aim of this retrospective case-
controlled study was to identify the subgroup of patients
that might benefit from non-high-dose PPI treatment.
Methods
Study design
We reviewed 477 consecutive medical records of sub-
jects with confirmed gastric and duodenal ulcers bleed-
ing by endoscopic study between Jan. 2009 and March.
2011. All subjects received endoscopic hemostatic ther-
apy for high-risk stigmata (active bleeding or a visible
vessel in an ulcer bed) and were prescribed intravenous
pantoprazole. The non-high-dose PPI patients were
those who received an 80 mg pantoprazole bolus, which
was followed by intravenous pantoprazole 80 mg per
day until alimentation was possible, and then they
received 40 mg per day pantoprazole orally. On the
other hand, high-dose PPI patients received an 80 mg
pantoprazole intravenous bolus injection, then were
treated with 8 mg per hour continuous infusion of pan-
toprazole for 3 days, which was followed by intravenous
80 mg per day. A video endoscope (Olympus GIF-
XQ240 or GIF-XQ 260, Tokyo, Japan) was used to per-
form the endoscopic therapy on all patients at our hos-
pital. Individuals were excluded if the ulcer was
malignant; there was non ulcerative bleeding such as
angiodysplasia or a Mallory-Weiss tear, if the subject
was lost to follow up before 30 days except due to mor-
tality, and if the patient did not successfully undergo the
initial endoscopic hemostasis. A total of 413 patients
were enrolled for further analysis. For comparison, the
patients were classified into two groups: subjects who
achieved sustained hemostasis (n = 324) and those who
did rebleed (n = 89). The patients’ demographic and
clinical characteristics were recorded including age, gen-
der, initial shock status, red blood cell count, the
amount of blood transfusion as packed red blood cells
(PRBC), time to endoscope, underlying morbidities, drug
use, such as non-steroid anti-inflammatory drugs
(NSAIDs), aspirin, clopidogrel or warfarin and the Rock-
all score calculated as described in a previous study
[15]. The characteristics of the ulcer, such as size, the
presence of multiple ulcers in association, and the Forr-
est classification, which was determined as described in
a previous study, were also investigated [16,17].
Next nearest neighbor matching was implemented
using the greedy matching algorithm (NCSS 2007, Kays-
ville, Utah 84037, USA) to reduce bias in this retrospec-
tive study. This matching algorithm was performed to
find equivalent matched controls in high-dose pantopra-
zole group for each individual in the non-high-dose
group. The matching variables were stage of chronic
kidney disease (CKD), Forrest classification and Rockall
score. Effectively, patients were randomly selected to
form non-high-dose and high-dose PPI groups that had
a high risk PU bleeding (n = 104 in each group); these
groups were then subdivided to two subgroups, namely
those with a Rockall score of ≥ 6, n = 77 and those with
a Rockall score of ≤ 6, n = 27). Risk stratification was
defined according to the Rockall scoring system.
Patients with a score ≧ 6w e r ec o n s i d e r e dh i g hr i s k
patients. Otherwise, they were classified as low risk
patients as validated by Church and colleagues [18].
This study was approved in accordance with the princi-
ples of the Helsinki Declaration by both the Institutional
Review Board and the Ethics Committee of Chang Gung
Memorial Hospital, Taiwan (IRB 100-2003B).
Liang et al. BMC Gastroenterology 2012, 12:28
http://www.biomedcentral.com/1471-230X/12/28
Page 2 of 8Definitions
The classification of chronic kidney disease was defined
according to Kidney Disease: Improving Global Out-
comes (KDIGO) [19]. The primary end points were
rebleeding, need for surgery, and mortality. Rebleeding
was defined based on the clinical physician’se v a l u a t i o n
as ongoing melena passage, hematemesis, fresh blood or
coffee-ground material in nasogastric tube or a decline
in the hemoglobin level with or without PRBC transfu-
sion. Shock was defined as tachycardia, a heart rate >
100/min, or hypotension with a systemic blood pressure
< 90 mmHg [14,20].
High risk ulcers were defined according to the Forrest
classification [16]. With respect to high-risk stigmata,
active bleeding was defined as a continuous blood spurt-
ing (Forrest IA) or oozing (Forrest IB) from the ulcer
base. A non-bleeding visible vessel at endoscopy was
defined as a discrete protuberance at the ulcer base
(Forrest IIA). An adherent clot was one that was resis-
tant to forceful irrigation or suction (Forrest IIB). With
respect to low-risk stigmata, a flat base, a pigmented
spot or a clean base were defined as Forrest grade IIC
or III.
Statistical analysis
The Statistical Package for Social Sciences (SPSS15.0,
Chicago, IL, USA) for Windows was used to analyze the
data. The results are expressed as distributions, absolute
frequencies, relative frequencies, medians and ranges, or
means ± standard deviation (SD). The quantitative data
were compared using the Student’s t-test when the vari-
ables had a normal distribution. Differences between the
proportions of categorical data were evaluated by Fish-
er’s exact test when the number of expected subjects
was less than five and otherwise by the c
2 test. A multi-
variate logistic regression model was used to assess the
independent association between the rebreeding and
non-rebleeding groups. A p value of < 0.05 was consid-
ered statistically significant. Further statistical analysis
was performed after case-controlled matching the sub-
groups with Rockall scores ≥ 6 or < 6 by the greedy
methods in order to compare rebleeding between the
high-dose and non-high-dose PPI groups.
Results
Among the 477 subjects who had their health records
reviewed, four subjects were lost to follow up before 30
days other than by death, two subjects failed their initial
endoscopic hemostasis, thirteen suffered from angiodys-
plasia, twenty five had gastric cancers, seventeen had
gastric antral vascular ectasia and three had a Mallory-
Weiss tear; these individuals were all excluded and
eventually 413 subjects were enrolled for further analy-
sis. Among these 413 enrolled patients, 219 were treated
by endoscopic epinephrine injection, clips or thermocoa-
gulation alone and 194 were treated by clips, or thermo-
coagulation in combination with epinephrine injection.
There were no significant differences between the two
study groups with respect to sustained hemostasis vs.
rebleeding groups in terms of age, drug use (such as
NSAIDs, aspirin or warfarin), shock at presentation,
time to endoscopy, ulcer size and stage of Forrest classi-
fication(Table 1). Significant differences were observed
for variables such as gender (female: 26.8% vs. 39.3%, p
= 0.022), creatinine (2.0 ± 2.3 g/L vs. 3.6 ± 3.3 g/L, p =
0.010), initial hemoglobin level (96.7 ± 28.2 g/L vs. 82.5
±2 4 . 1g / L ,p ≤ 0.001), platelet count (197.4 ± 87.3 ×
10
9/L vs. 188.0 ± 129.0 × 10
9/L, p = 0.031), CKD stage
III to V (38.9% vs.7 0 . 8 % ,p ≤ 0.001), DM (26.9% vs.
41.6%, p = 0.007), Rockall score (6.0 ± 1.6 vs. 6.8, ± 17,
p < 0.001), amount of blood transfused as PRBC (1203.2
± 1640.4 mL vs. 2192.6 ± 2077.3 mL, p < 0.001), surgery
(0.3 vs.7.9, p < 0.001), hospital stay (11.5 ± 13.5 vs. 29.9
±4 6 . 0 ,p < 0.001)and mortality (6.8% vs.2 9 . 2 % ,p <
0.001). On multivariate analysis, an initial low hemoglo-
bin level, serum creatinine level, and Rockall score were
independent factors associated with rebleeding (Table
2).
The greedy method (NCSS 2007) was used to create
treatment-control random matching of individuals based
on stage of CKD and Rockall score, and 104 patients
were randomly selected to form the non-high-dose and
high-dose patient groups (Table 3). Among high risk
patients (n = 77), the significant variables were the
rebleeding rate (14.3% vs. 40.2%, p = 0.001), and amount
of blood transfused as PRBC (1373.4 ± 1309.5 mL vs.
2539.0 ± 2271.1 mL, p ≤ 0.001). On the other hand,
among the low risk patients (Rockall score ≤ 6), the
baseline demographic and clinical characteristics such as
rebleeding rate (3/27, 11.1% in each group), surgical
interventions, and mortality were similar for both the
high-dose and non-high-dose groups (Table 4).
Discussion
There have been a number of studies in the literature
that have reported there to be no difference in the mag-
nitude of risk reduction between intensive high-dose
and non-high-dose intravenous PPI therapy and these
include those conducted by the Hung and Yuksel groups
[9,21]. In addition, meta-analysis by Wang and Wu
came to a similar conclusion, namely that low-dose
intravenous PPI can achieve the same efficacy as high-
dose PPI following endoscopic hemostasis [22,23]. A
more recent prospective study conducted by Songür and
colleagues also showed that high-dose esomeprazole
infusion therapy following endoscopic hemostasis treat-
ment is not superior to low-dose PPI therapy in the
terms of re-bleeding, need for surgery and mortality
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cluded in a randomized clinical trial that PPI dosage is
not associated with rebleeding following combined
endoscopic haemostasis of bleeding ulcers [25].
Obviously, the findings remain somewhat unconvincing
with respect to the optimal dosage of PPI for ulcer
bleeding despite the publication of updated Vienna and
Asian-pacific consensus statements [10,11]. In parallel
with the above findings, we still do not know whether
t h ee f f e c to fi n t r a v e n o u sn o n - h i g h - d o s eP P I si sa sg o o d
as high-dose PPIs in terms of reducing rebleeding rates
among patients at low risk (Rockall score ≤ 6) or among
those at high risk (Rockall score ≥ 6).
The overall rebleeding rate in current study was high
at 21.5% (89/413) with Hung and Yuksel reported
rebleeding rates of 3.9% (4/103) and 7.2% (7/97), respec-
tively [9,21]. The differences can be explained by the
enrollment in the present study of more patients with
concurrent illness resulting in a mean Rockall score of
6.1. The prevalence of CKD in Yuksel’ss t u d yw a so n l y
2.06% (2/97), and the mean score of American Society
of Anesthesiologist (ASA) criteria was only 1.5 to 1.6 in
Hung’s study. As is well known, severe concurrent ill-
ness may dilute the results attained when assessing the
effect of high-dose PPI treatment. All these studies,
including ours, observed that intravenous high-dose
pantoprazole treatment did not appear to be more effec-
tive at reducing rebleeding compared to a non-high-
dose regimen among patients with high-risk stigmata.
Table 1 Basic demographic and clinical characteristics of all enrolled patients
Variables Sustained Hemostasis (n = 324) Rebleeding (n = 89) p-value
Age (years) 64.8 ± 13.9 66.4 ± 13.2 0.812
Female gender, n (%) 87(26.8) 35(39.3) 0.022*
Hb (g/L) 96.7 ± 28.2 82.5 ± 24.1 < 0.001*
Creatinine 2.0 ± 2.3 3.6 ± 3.3 < 0.001*
Platelet (× 10
9/L) 197.4 ± 87.3 188.0 ± 129.0 0.031*
Use of NSAIDs, n (%) 29(9.0) 4(4.5) 0.170
Use of aspirin, n (%) 60(18.5) 9(10.1) 0.060
Use of clopidogrel, n (%) 38(11.7) 11(12.4) 0.870
Use of wafarin, n (%) 15(4.6) 5(5.6) 0.700
Shock on admission, n (%) 165(50.9) 53(59.6) 0.149
Coexisting illness, n (%)
CKD III to V 126(38.9) 63(70.8) < 0.001*
COPD 22(6.8) 7(7.9) 0.725
CAD 62(19.1) 23(25.8) 0.166
DM 87(26.9) 37(41.6) 0.007*
CVA 54(16.7) 20(22.5) 0.206
Liver Cirrhosis 55(17.0) 12(13.5) 0.429
Rockall score 6.0 ± 1.6 6.8 ± 1.7 < 0.001*
Time to endoscope (h) 14.7 ± 13.6 18.5 ± 20.3 0.333
Ulcer size (cm) 1.0 ± 0.6 1.0 ± 0.6 0.884
Multiple ulcers, n (%) 105(32.4) 36(40.4) 0.156
High stigmata in Forrest classification, n (%) 316(97.5) 86(96.6) 0.640
PRBC BT(mL) 1203.2 ± 1640.4 2192.6 ± 2077.3 < 0.001*
Surgery, n (%) 1(0.3) 7(7.9) < 0.001*
Hospital stay(days) 11.5 ± 13.5 29.9 ± 46.0 < 0.001*
Mortality, n (%) 22(6.8) 26(29.2) < 0.001*
Bleeding related/Other causes 5/17 14/12
Abbreviations: OR, odds ratio; CI, confidence interval; Hb, hemoglobin; CKD, chronic kidney disease; NSAID, nonsteriodal anti-inflammatory drug; PPI, proton-pump
inhibitor; DM, diabetes mellitus type 2; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; CVA, cerebrovascular accident; BT, blood
transfusion. * p < 0.05
Table 2 Predictors of recurrent bleeding from stepwise
logistic regression in the multivariate analysis
Odds ratio 95% CI. p-value
Hb (g/L) 0.877 0.791-0.972 0.012
Creatinine 1.144 1.050-1.247 0.002
Rockall score 1.201 1.021-1.412 0.027
Abbreviation: Hb, hemoglobin; CI: Confidence interval
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trolled study like the current study is that, despite the
attempt to minimize the possible selection bias between
the two treatment groups by conducting greedy match-
ing, prejudice is still inevitable among the high-dose
group. For instance, there were still more rebleeding
patients in the high risk patients with Rockall score ≥ 6
(14.3% vs. 40.2%, p = 0.001).
Most interestingly, after case-controlled matching, the
low risk patient subgroup (Rockall score ≤ 6) analysis
actually showed that the rebleeding rate was similar for
both the high-dose and non-high-dose groups (3/27,
11.1% in each group) (Table 4). This implies that non-
high-dose intravenous PPI is enough to preventing
rebleeding among low risk patient. Theoretically, there
is no doubt about the effectiveness of the anti-secretory
effect of high-dose PPI. Evidence points clearly towards
t h ef a c tt h a tc o n t i n u o u si n t ravenous infusion of PPI is
able to maintain an intragastric pH > 6 for 59% to 98%
of the time during monitoring [26-28]. In contrast,
other studies have shown that low-dose intravenous PPI
can be as effective as a high-dose regimen at maintain-
ing a consistent pH of around 4-6 [29,30]. Choi and col-
leagues reported that low-dose continuous infusion of
pantoprazole (40 mg bolus followed by 4 mg/h) was
able to maintain an intragastric pH > 6 in a manner
similar to that of a high-dose group (80 mg bolus fol-
lowed by 8 mg/h) among Korean patients with PU
bleeding requiring endoscopic hemostasis [31]. At least
two other meta-analysis studies have revealed that high-
dose PPIs are not superior to non-high-dose PPIs in
terms of reducing the rate of rebleeding, neither with
respect to the need for surgical intervention, nor in
terms of mortality after endoscopic treatment among
Table 3 Comparison between the non-high-dose and high-dose groups of patients after randomly matched analysis
by using Greedy method
Characteristic Non-high-dose Group (n = 104) High-dose Group (n = 104) P-value
Age (years) 65.6 ± 11.8 65.5 ± 13.9 0.258
Female gender, n (%) 24(23.1) 39(37.5) 0.024*
Creatinine(mg/dl) 2.4 ± 2.3 2.8 ± 2.9 0.010*
Hb (g/L) 88.9 ± 25.2 89.1 ± 27.6 0.386
Platelet(× 10
9/L) 191.5 ± 88.8 198.9 ± 106.3 0.113
Use of NSAIDs, n (%) 9(8.7) 11(10.6) 0.638
Use of aspirin, n (%) 15(14.4) 18(17.3) 0.569
Use of clopidogrel, n (%) 11(10.6) 13(12.5) 0.664
Use of wafarin, n (%) 6(5.8) 10(9.6) 0.298
Shock at presentation 52(50.0) 65(62.5) 0.069
Coexisting illness, n (%)
CKDIII, IV/V 40/14 (38.5/13.5) 40/15(38.5/14.4) 0.978
COPD 7(6.7) 6 (5.8) 0.775
CAD 19(18.3) 28(26.9) 0.136
DM 34(32.7) 39(37.5) 0.468
CVA 21(20.2) 23(22.1) 0.734
Liver Cirrhosis 20(19.2) 14(13.5) 0.261
Rockall score 6.4 ± 1.4 6.4 ± 1.4 1.000
Time to endoscope (h) 16.4 ± 20.3 16.9 ± 19.8 0.482
PRBC BT(mL) 1252.4 ± 1272.1 2156.3 ± 2117.1 0.007
Ulcer size (cm) 1.0 ± 0.6 0.9 ± 0.6 0.901
Multiple ulcers, n (%) 29(27.9) 38(36.5) 0.182
Forrest classification Ia/Ib/IIa/IIb/IIc/III 2/70/6/26/0/0 3/70/6/25/0/0 0.974
Re-bleeding, n (%) 14 (13.5) 34 (32.7) 0.001*
Surgery, n (%) 2(1.9) 1(1.0) 0.561
Hospital stay (days) 13.9 ± 22.3 17.9 ± 15.3 0.641
Mortality, n (%) 10(9.6) 16(15.4) 0.403
Bleeding related/Other causes 4/6 8/8
Abbreviation: Hb, hemoglobin; NSAID, nonsteriodal anti-inflammatory drug; CKD, chronic kidney disease; PPI, proton-pump inhibitor; DM, diabetes mellitus type 2;
COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; CVA, cerebrovascular accident; BT, blood transfusion. * p < 0.05
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high dose PPI treatment strategy may provide an equal
clinical benefit among ulcer bleeding patients [24,25,32].
Therefore, it makes sense that non-high-dose intrave-
nous PPI might be sufficient to reduce the rebleeding of
PUs after initial endoscopic hemostasis among Taiwa-
nese, at least among the subgroup of low risk patients
that have a Rockall score < 6.
Co-morbidities influence the rate of recurrent bleeding
[33]. Recurrent PU bleeding may be prolonged in indivi-
duals with co-morbidities and therefore Cheng and col-
leagues suggested a extended low dose infusion of
intravenous PPIs for up to 7-days may result in better
control of recurrent bleeding of PUs [13]. For instance,
the fact that patients have a more severe stage of kidney
disease (CKD V) might be relevant to increased rebleed-
ing [34]. This is consistent with the present study in
that CKD stage III to V was found to be an influencing
risk factor for recurrent bleeding on univariate analysis
in spite of the fact that all subjects with end stage renal
disease (ESRD) received heparin-free dialysis at our hos-
pital. Uremic platelet function impairment may be
responsible for this higher risk of ulcer rebleeding [35].
The reason behind uremic platelet dysfunction involving
the interaction of von Willebrand factor (vWf) with var-
ious platelet membrane glycoproteins, namely Ib and IIb
to IIIa, which do not normalize after dialysis [36].
From the cost-effectiveness point of view, Leontiadis
and colleagues reported that high-dose PPI therapy is
more expensive, and that non-high dose is relatively
inexpensive [37]; however, Barkun and colleagues
proved that high-dose intravenous esomeprazole strategy
is more effective and less costly than a non-intravenous
esomeprazole strategy [38].
Several limitations of this study must be recognized.
Firstly, this retrospective analysis is dependent on the
Table 4 Comparison between the intravenous non-high-dose and high-dose PPI after case-controlled matching for the
subgroup of low risk patients (Rockall score < 6)
Characteristics Non-high-dose Group (n = 27) High-dose Group (n = 27) p-value
Age (years) 65.8 ± 3.8 62.4 ± 14.7 0.991
Female gender, n (%) 4(14.8) 10(37.0) 0.119
Creatinine(mg/dl) 1.3 ± 0.5 1.5 ± 1.5 0.100
Hb (g/L) 95.4 ± 25.1 106.0 ± 29.9 0.340
Platelets (× 10
9/L) 202.2 ± 81.1 246.5 ± 91.6 0.151
Use of NSAIDs, n (%) 3(11.1) 5(18.5) 0.704
Use of aspirin, n (%) 2(7.4) 1(3.7) 1.000
Use of clopidogrel, n (%) 1(3.7) 2(7.4) 1.000
Use of wafarin, n (%) 1(3.7) 3(11.1) 0.610
Shock at presentation 9(33.3) 11(40.7) 0.573
Coexisting illness, n (%)
CKD III, IV and V 7(25.9)/0 7(25.9)/0 1.000
COPD 1(3.7) 0 1.000
CAD 2(7.4) 2(7.4) 1.000
DM 7(25.9) 8(29.6) 0.761
CVA 3(11.1) 5(18.5) 0.704
Liver Cirrhosis 1(3.7) 1(3.7) 1.000
Rockall score 4.5 ± 0.6 4.5 ± 0.6 1.000
Time to endoscopy (hours) 10.4 ± 11.3 10.6 ± 9.9 0.904
PRBC BT(mL) 907.4 ± 1109.7 1064.8 ± 1003.8 0.863
Ulcer size (cm) 1.1 ± 0.7 0.9 ± 0.6 0.506
Multiple ulcers, n (%) 7(25.9) 9(33.3) 0.182
Forrest classification Ia/Ib/IIa/IIb 0/18/2/7 0/18/2/7 1.000
Re-bleeding, n (%) 3(11.1) 3 (11.1) 1.000
Surgery, n (%) 0 0 1.000
Hospital stay (days) 5.7 ± 5.6 11.7 ± 8.6 0.031*
Mortality, n (%), bleeding related and other causes 0/0 0/1 (3.7) 1.000
Abbreviation: Hb, hemoglobin; NSAID, nonsteriodal anti-inflammatory drug; CKD, chronic kidney disease; PPI, proton-pump inhibitor; DM, diabetes mellitus type 2;
COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; CVA, cerebrovascular accident; BT, blood transfusion. * p < 0.05
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of ulcer pattern was not complete, we reviewed the
image obtained by endoscopy or watching the recorded
video in order to record the ulcer characteristics. There-
fore, the investigation reliability might vary in this area.
Secondly, selection bias definitely existed among high-
dose group due to the clinicians’ decision with respect
to the dosage used for the more severely ill patients,
even though we attempted to minimize this selection
bias using the greedy matching method after controlling
the baseline conditions of the subjects. Thirdly, some
patients were treated by endoscopic epinephrine injec-
tion alone, which was suboptimal. Therefore, the inten-
tion to compare the overall efficacies between the non-
high-dose and high-dose PPIs is hampered by these lim-
itations. However, the interesting part of this study
remains our observed in terms of the low risk subgroup
and treatment strategy.
Conclusion
Intravenous non-high-dose pantoprazole is equally effec-
tive as high-dose pantoprazole when treating low risk
patients with bleeding ulcers and high-risk stigmata
a f t e re n d o s c o p i ch e m o s t a s i sa n dw h oh a v eaR o c k a l l
sore that is < 6.
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